News Summary
NeutralBio-Techne agreed to be acquired by Merck KGaA for $73/share ($11.3B), expected to close late 2026/early 2027, which dominates the investment narrative and has halted earnings call communications. Q4 FY2026 results showed flat full-year revenue growth and mixed analyst sentiment earlier in the year, though the acquisition price is viewed as strategically sound by the market.
Red flags
- •Full-year organic revenue growth flat at 0%
- •Diagnostics and Spatial Biology segment sales declined 3% year-over-year
- •Multiple analyst downgrades in H1 2026 citing softer organic growth and weaker free cash flow margins
- •Adjusted EPS declined slightly in Q4 ($0.52 vs $0.53)
- •Company suspended investor conference calls, limiting transparency during acquisition period
Funds Reducing / Exiting (4)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Maverick Capital | Lee Ainslie | 1.5M | -3,203,927 | $108M | 2.9% | -68% | Existing |
| Durable Capital Partners | Henry Ellenbogen | 502K | -3,955,968 | $35M | 2.4% | -89% | Existing |
| Glenview Capital | Larry Robbins | 58K | -128,015 | $4M | 0.3% | -69% | Existing |
| Point72 | Steve Cohen | 0 | −295K | — | <0.1% | -100% | EXITED |
Shares Held reflects quarter-end positions for partial reductions. Funds that fully exited show 0 shares held. ∆ Shares is the change from the prior quarter. % of Fund is the prior-quarter position size — how much of the book was sold down.
Signal History
| Quarter | Direction | Funds | Score | vs SPY |
|---|---|---|---|---|
| Q2 2026 | SHORT | 4 | 3.88 | +0.2% |
| Q1 2026 | LONG | 3 | 3.85 | +19.1% |
Same issuer appearing in consecutive quarters — persistent institutional conviction. Returns are frozen at each archived quarter's last refresh.
Beneficial Ownership (13D/13G)
| Filer | Form | Shares | % of Class | Filed | Src |
|---|---|---|---|---|---|
| FMR LLC | SC 13G/A | 12.8M | 8.1% | 2026-08-06 | ↗ |
| FMR LLC | SC 13G | 7.9M | 5.0% | 2026-05-06 | ↗ |
| Vanguard Capital Management | SC 13G | 11.6M | 7.4% | 2026-04-29 | ↗ |
SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.